Share Coloplast trading with a premium in pharmaceutical sector

The Danish stock Coloplast is currently traded with one the highest CAPE-ratios of the pharmaceutical companies. Currently the share is now traded at 112 times the past 10 year's average EPS (CAPE / Shiller PE). With this the stock trades way higher than the average US stock of the pharmaceutical companies which now costs 14 times the average 10-years EPS.

Core figures US pharmaceutical companies

We further see that over the past year the American pharmaceutical companies yielded 15 percent higher. They performed better than the European sector that yielded 15 percent higher. The American sector trades with a CAPE-ratio of 5 and the European sector trades at 47. The CAPE-ratios level doesn't seemt to have a relation with the price returns as the higher returns don't all have higher CAPE-ratios.

For this year Coloplast 's revenue will be around 17,95 billion Danish Krone. This is according to the average of the analysts' estimates. This is slightly more than 2017's revenue of 16,45 billion Danish Krone.

Historical revenues and results Coloplast plus estimates 2018

The analysts expect for 2018 a net profit of 4,28 billion Danish Krone. Most of the analysts anticipate on a profit per share of 20,23 Danish Krone. So the price/earnings-ratio equals 30,47.

Analysts expect a dividend of 17,18 Danish Krone per share. Coloplast 's dividend yield thus equals 2,79 percent. The average dividend yield of the pharmaceutical companies equals a moderate 0,5 percent.

Coloplast 's market capitalization is based on the number of outstanding shares around 119,7 billion Danish Krone. The Coloplast stock was the past 12 months quite unstable. Since last November the stock is even 23 percent higher. This year the stock price moved between 474 and 717 DKK. Since 2008 the stock price is almost 694 percent higher.

Historical stock prices Coloplast past 10 years

At 9.19 the stock trades 0,84 percent higher at 616,4 Danish Krone.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.